Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
611
datasets available to search
ShareScore release 0.9.0
Dataset results
611 results for “AMYOTROPHIC LATERAL SCLEROSIS”
Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov study NCT00424463. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov study NCT03168711. IPD Sharing: NO. Countries: 1. Publications: 4.
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
ClinicalTrials.gov study NCT05178810. IPD Sharing: Not stated. Countries: 11. Publications: 0.
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov study NCT03127514. IPD Sharing: YES. Countries: 1. Publications: 5.
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov study NCT00790582. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov study NCT04944784. IPD Sharing: NO. Countries: 16. Publications: 4.
High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis
ClinicalTrials.gov study NCT00983983. IPD Sharing: Not stated. Countries: 1. Publications: 9.
Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis
ClinicalTrials.gov study NCT04176224. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
ClinicalTrials.gov study NCT04998305. IPD Sharing: NO. Countries: 1. Publications: 1.
A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov study NCT02288091. IPD Sharing: NO. Countries: 1. Publications: 3.
Early-onset sleep alterations found in patients with amyotrophic lateral sclerosis are ameliorated by orexin antagonist in mouse models
Open the record for dataset details and reuse information.
Electroencephalography of completely locked-in state patients with amyotrophic lateral sclerosis
<p>The data set includes raw EEG data for 10 completely locked-in state (CLIS) patients with amyotrophic lateral sclerosis (ALS) and 6 healthy participants. The EEG data were recorded during resting state and the reference was right mastoid. This data was used in the publication https://doi.org/10.1016/j.neures.2020.01.013.</p>
Data from: Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis
<p><span><b>Objective</b> To determine whether lipids and apolipoproteins predict prognosis of patients with amyotrophic lateral sclerosis in a cohort study of 99 amyotrophic lateral sclerosis patients who were diagnosed during 2015-2018 and followed until October 31, 2018, at the Neurology Clinic in Karolinska University Hospital in Stockholm, Sweden. </span></p> <p><span><b>Methods</b> Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, apolipoprotein A-I, apolipoprotein B, and lipid ratios were measured at the time of amyotrophic lateral sclerosis diagnosis or shortly thereafter. Death after amyotrophic lateral sclerosis diagnosis was used as the main outcome. Cox model was used to estimate hazard ratios with 95% confidence intervals of death after amyotrophic lateral sclerosis diagnosis, after controlling for sex, age at diagnosis, site of symptoms onset, diagnostic delay, body mass index, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, and progression rate.</span></p> <p><span><b>Results </b>One-standard deviation increase of total cholesterol (hazard ratio, 0.60; 95% confidence interval, 0.41-0.89; P=0.01), low-density lipoprotein cholesterol (hazard ratio, 0.64; 95% confidence interval, 0.44-0.92; P=0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (hazard ratio, 0.65; 95% confidence interval, 0.46-0.92; P=0.02), apolipoprotein B (hazard ratio, 0.62; 95% confidence interval, 0.44-0.88; P=0.01), or apolipoprotein B/apolipoprotein A-I ratio (hazard ratio, 0.61; 95% confidence interval, 0.43-0.86; P<0.01) were all associated with a lower risk of death after amyotrophic lateral sclerosis diagnosis. A dose-response relationship was also noted when analyzing these biomarkers as categorical variables. </span></p> <p><span><b>Conclusions </b>Lipids and apolipoproteins are important prognostic indicators for amyotrophic lateral sclerosis and should be monitored at the diagnosis of amyotrophic lateral sclerosis.</span></p>
Data from: Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials
Objective: To assess the effect of eligibility criteria on exclusion rates, generalizability and outcome heterogeneity in ALS clinical trials, and to assess the value of a risk-based inclusion criterion. Methods: A literature search was performed to summarize eligibility criteria of clinical trials. The extracted criteria were applied to an incidence cohort of 2,904 consecutive ALS patients to quantify their effects on generalizability and outcome heterogeneity. We evaluated the effect of a risk-based selection approach on trial design using a personalized survival prediction model. Results: We identified 38 trials: enrolled patients reveal a large variability between trials of all patient characteristics (p < 0.001), except for the proportion of males (p = 0.21). Exclusion rates varied widely (from 14% to 95%; mean 59.8% (95% CI 52.6-66.7)). Stratification of the eligible populations into prognostic subgroups showed that eligibility criteria lead to exclusion of patients in all prognostic groups. Eligibility criteria neither reduce heterogeneity in survival time (from 22.0 to 20.5 months, p = 0.09) nor affect between-patient variability in functional decline (from 0.62 to 0.65, p = 0.25). In none of the 38 trials were the eligibility criteria found to be more efficient than the prediction model in optimizing sample size and eligibility rate. Conclusions: The majority of ALS patients are excluded from trial participation, which questions the generalizability of trial results. Importantly, eligibility criteria only minimally improve homogeneity in trial endpoints. An individualized risk-based criterion could be used to balance the gains in trial design and loss in generalizability.
Dataset related to article "Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia"
<p>Dataset related to the article 10.1093/brain/awab333</p>
Ozone modified hypothalamic signaling enhancing thermogenesis in the TDP-43A315T transgenic model of Amyotrophic Lateral Sclerosis
<p><strong>Illumina sequencing and analysis</strong></p>
Data from: Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum
<p>Objective: We aimed to characterize cortical macro- and micro-structure of behavioral and cognitive changes along the amyotrophic lateral sclerosis (ALS) – frontotemporal dementia (FTD) continuum.</p> <p>Methods: We prospectively recruited 88 participants with a three-Tesla MRI structural and diffusion-weighted imaging sequences: 31 ALS, 20 bvFTD, and 37 cognitively normal controls. ALS participants underwent a comprehensive cognitive and behavioral assessment and were dichotomized in ALS without cognitive or behavioral impairment (ALSno-cbi, n=12) and ALS with cognitive or behavioral impairment (ALScbi, n=19). We computed cortical thickness and cortical mean diffusivity using a surface-based approach and explored the cortical correlates of cognitive impairment with the Edinburgh Cognitive and Behavioral Amyotrophic lateral sclerosis Screen (ECAS). </p> <p>Results: ALSno-cbi and ALScbi groups showed different patterns of reduced cortical thickness and increased cortical mean diffusivity. In the ALSno-cbi group, cortical thinning was mainly restricted to the dorsal motor cortex. In contrast, in the ALScbi group, cortical thinning was observed primarily on fronto-insular and temporal regions bilaterally. There were progressive cortical mean diffusivity changes along the ALSno-cbi, ALScbi, and bvFTD clinical continuum. Importantly, ALS participants with either cognitive or behavioral impairment showed increased cortical mean diffusivity in the prefrontal cortex in the absence of cortical thickness. </p> <p>Conclusions: Cortical mean diffusivity might be a useful biomarker for the study of extra motor cortical neurodegeneration in the ALS-FTD clinical spectrum.</p>
Atrophy Pattern Maps of Amyotrophic Lateral Sclerosis (ALS)
<p>The files contain voxel-wise t-statistics maps showing deformation based morphometry (DBM) based atrophy patterns as well as their longitudinal changes in amyotrophic lateral sclerosis (ALS) patients.</p> <p>For more information regarding the participants and method details, see:</p> <p>Dadar, Mahsa, et al. "Cerebral atrophy in amyotrophic lateral sclerosis parallels the pathological distribution of TDP43." <em>Brain Communications</em> 2.2 (2020): fcaa061.</p>
Dataset related to article "BEHAVIORAL AND COGNITIVE PHENOTYPES OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS CARRYING SOD1 VARIANTS"
<p><strong>ngs_analysis performedn as part of the study mentioned at title</strong></p>
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
ClinicalTrials.gov study NCT02794857. IPD Sharing: Not stated. Countries: 2. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.